Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 2/3 1Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Breast 1

Conditions

Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × GDC-0084 × Clear all
NCT03765983 2026-05-27

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
17 enrolled 14 charts
Breast

Breast Neoplasms

NCT05009992 2025-12-17

PNOC022

University of California, San Francisco

Phase 2 Recruiting
360 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT03522298 2025-03-24

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

Kazia Therapeutics Limited

Phase 2 Completed
30 enrolled 27 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡